Deliver Your News to the World

CybeRelease: (OTC PK: MNCL) Seeks Distribution Rights for the Treatment of Male Testosterone Deficiency


(CybeRelease, February 23, 2007) - Lake Harmony, PA - Martin Nutraceuticals Inc. (OTC PK: MNCL) today announced the finalizing of an agreement for distribution rights of CGY-25(R) with NormallyPharma for Canada, and is in final negotiations for the distribution rights for the United States.

CGY-25 is for the treatment of male testosterone deficiency also commonly referred to as andropause. CGY-25 stimulates the secretion of a male sex hormone in the Leydig cells for the natural treatment of testosterone deficiency. It is estimated that testosterone deficiency or andropause directly affects more than 11 million men in North America and is believed to have a correlation with Erectile Dysfunction (ED), which affects upwards of 30 million North American men. Treatment of (ED) and other related erectile deficiency’s is a $3.5+B business today via prescribed drugs, most notably, Viagra, Cialis and Levitra. Despite the dominance of these products, several opportunities exist for a successful market entry.

According to the market research firm ImpactRx, which tracks the habits of a panel of high prescribing physicians and may reflect emerging trends in doctors’ offices today. Upon the introduction of a NEW drug (Cialis) for (ED) in 2004, U.S. urologists initiated treatment with Cialis at a rate of more than two-to-one over each of the other oral ED treatments. In fact, the NEW drug, Cialis, represented 56 percent of new treatment initiations by urologists compared to 21 percent for Levitra and 23 percent for Viagra.

To read the complete release, go to

For a Free Newsletter, go to

CybeRelease Gainers are Linear Technology Corporation (Nasdaq: LLTC), Maxim Integrated Products, Inc. (Nasdaq: MXIM), Intersil Corporation (Nasdaq: ISIL), Microchip Technology Incorporated (Nasdaq: MCHP), Microsemi Corporation (Nasdaq: MSCC), Energy Conversion Devices, Inc. (Nasdaq: ENER), Wynn Resorts, Limited (Nasdaq: WYNN) and Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP).

CybeRelease Decliners are Research in Motion Limited (Nasdaq: RIMM), Comcast Corporation (Nasdaq: CMCSK), Patterson Companies Inc. (Nasdaq: PDCO), Crocs, Inc. (Nasdaq: CROX), K-Swiss Inc. (Nasdaq: KSWS), NutriSystem Inc. (Nasdaq: NTRI), UAL Corporation (Nasdaq: UAUA) and Hyperion Solutions Corporation (Nasdaq: HYSL).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for informational purposes only and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.